Browse the evidence

Use of GLP-1 receptor agonists (GLP-1 RAs) significantly reduces the risk of developing lymphedema in patients undergoing axillary lymph node dissection (ALND) for breast cancer, independent of diabetes status.

If you are having breast cancer surgery that involves removing lymph nodes, ask your doctor if GLP-1 RAs (like semaglutide or liraglutide) might help reduce your risk of lymphedema, especially if you have a higher BMI or insulin resistance. The study suggests these drugs may significantly lower the risk, but more research is needed to confirm this.

Implantation of alginate-encapsulated engineered HEKGLP-1 cells in mice, activated by endogenous or exogenous melatonin, produces GLP-1 specifically during the night phase, restoring normoglycemia in type-2 diabetic models.

This research proposes a future therapy where genetically engineered cells are implanted and protected in a capsule. These cells produce the diabetes drug GLP-1 only when melatonin levels are high (at night). Patients could take oral melatonin to control how much GLP-1 is produced, potentially allowing for once-daily dosing instead of weekly injections. This is currently only proven in mice.

Combined GIPR/GLP1R agonism significantly attenuates atherosclerosis severity (shifting lesions from severe to mild) in APOE*3-Leiden.CETP mice, an effect not achieved by single GIPR or GLP1R agonism.

This pre-clinical study suggests that combining GIP and GLP-1 receptor agonism may offer superior protection against atherosclerosis severity compared to using either hormone alone. For humans, this supports the development and use of dual-agonist therapies (like tirzepatide) for cardiovascular risk reduction, particularly in those with obesity and dyslipidemia, though clinical confirmation is required.

In obese patients without preexisting osteoarthritis, GLP-1 receptor agonist use is associated with an increased incidence of new hip and knee OA diagnoses and conversion to total knee arthroplasty within one year.

If you are obese but do not have existing hip or knee osteoarthritis, using a GLP-1 receptor agonist is associated with a higher risk of being diagnosed with new OA or needing knee replacement surgery within a year. This is unexpected given the weight loss benefits, and researchers suggest it might be due to increased physical activity stressing the joints. If you are considering these medications, discuss your joint health history with your doctor, and be aware that the benefits for joint health may primarily apply to those who already have OA.

Long-term administration of the dual GLP-1/GIP receptor agonist tirzepatide suppresses mammary tumor growth in diet-induced obese mice by reversing metabolic dysregulation and restoring CD8+ T cell function.

For individuals with obesity and hormone-sensitive or obesity-linked cancers, GLP-1/GIP agonists like tirzepatide may offer a dual benefit of weight loss and tumor suppression by correcting metabolic dysregulation. This suggests that treating obesity pharmacologically could be a viable adjunct strategy in oncology, provided lean mass is monitored.

The proposed mechanism for this hearing loss is the suppression of matrix metalloproteinase-9 (MMP-9) by exendin-4 derivatives, leading to micro-platelet-erythrocyte clot formation and occlusion of cochlear micro-circulation.

This mechanism is currently theoretical. While it provides a plausible biological explanation for why Lixisenatide might affect hearing, it has not been directly proven in human trials yet.

Intestinal GLP-1 from colonic L-cells is likely not involved in the acute control of meal size or thirst, but may play a role in long-term fluid balance and cardiovascular function.

The GLP-1 produced in your large intestine (colon) likely doesn't help you feel full or stop drinking during a meal. Its role is more about long-term fluid and heart health regulation, distinct from the GLP-1 produced in the small intestine which helps control appetite.

DJB implantation is associated with a high rate of adverse events (13.2% early extraction) and serious complications, including liver abscesses and bleeding.

The DJB device carries a significant risk of complications, with 13.2% of patients requiring early removal due to adverse events like bleeding or liver abscesses. Patients must be aware of these risks before proceeding.

Tirzepatide (TZP) administration causes bone loss in obese diabetic mice by reducing gut microbiota biodiversity, specifically depleting Lachnospiraceae, which leads to lower levels of the metabolite evodiamine and subsequent increased osteoclastogenesis.

If you are taking Tirzepatide for diabetes or obesity, be aware that it may reduce bone density in your hips/femurs by altering gut bacteria. Discuss bone health monitoring with your doctor. The study suggests that maintaining gut health (specifically Lachnospiraceae bacteria) might protect bone, though probiotic supplementation is not yet a standard prescription.

Monogenic diabetes, representing 1-4% of diabetes cases in infants and young adults, is frequently misdiagnosed as Type 1 or Type 2 diabetes, leading to inappropriate therapeutic management and worsened prognosis.

If a child or young adult is diagnosed with diabetes, ask if genetic testing for monogenic forms has been considered. Misdiagnosis as T1 or T2 can lead to incorrect treatment and worse outcomes, as monogenic diabetes often requires specific therapies different from standard insulin or oral agents.

Routine antibiotic prophylaxis following uncomplicated vaginal delivery does not significantly reduce the incidence of postpartum infections and may contribute to antimicrobial resistance without clear clinical benefit.

For uncomplicated vaginal deliveries, routine antibiotic prophylaxis is not recommended as it does not reduce infection rates and contributes to antibiotic resistance. Focus on hygiene and monitoring for signs of infection rather than preemptive medication.

Machine learning-guided optimization of triple agonist peptides (GCGR, GLP1R, GIPR) using Graph Attention Networks and genetic algorithms generates peptide sequences with high predicted binding affinity across all three targets, demonstrating superior computational performance over traditional Convolutional Neural Networks for GCGR prediction.

This research does not yet offer a direct treatment for patients. It describes a computational method to design better diabetes and obesity drugs. The key takeaway is that using advanced AI (Graph Attention Networks) to design peptides that target three metabolic receptors (GCGR, GLP1R, GIPR) simultaneously is more effective than older methods. This could lead to more potent drugs in the future, but no such drug is currently available for clinical use based on this paper alone.

Knockout of the lineage-specific microprotein Adipocyte-smORF-1183 significantly impairs adipocyte differentiation and reduces lipid droplet formation by approximately 50% in 3T3-L1 cells.

This research identifies a specific microprotein (Adipocyte-smORF-1183) in mouse fat cells that helps store fat. Knocking it out reduces fat storage by half in these cells. This is a basic science discovery about how fat cells work and does not currently translate to a human treatment or supplement.

Perioperative GLP-1 receptor agonist therapy does not significantly reduce periprosthetic joint infection or revision rates in patients undergoing total knee arthroplasty.

If you are having knee replacement, current evidence does not show that GLP-1 agonists reduce infection or revision risk. Discuss with your surgeon, but do not expect the same benefits seen in hip surgery.

The new user rate of semaglutide (Ozempic ® ) remained stable at approximately 4 per 1000 adult person-years between 2019 and 2021 and then peaked at 10 per 1000 in the first quarter of 2023.

Practitioners should be aware of the increasing trend in semaglutide prescriptions, particularly in 2023.

Perioperative use of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) may increase the risk of bronchoaspiration.

Clinicians should be cautious about the use of GLP-1-RAs in the perioperative setting due to the risk of bronchoaspiration.

1.2% of boys and men aged 15 to 35 reported use of prescription weight loss medication in the past 12 months.

Practitioners should be aware of the low prevalence of prescription weight loss medication use in this demographic.

68% of respondents who took protein supplements were males and 32% were females.

Understanding the gender distribution can help tailor marketing and educational efforts regarding protein supplements.

There is no relationship between protein intake and nutritional status.

Protein intake may not be a critical factor in assessing nutritional status in this population.

Inhibiting miR-30e-5p using antagomirs reduces atherosclerosis in obese mouse models by restoring SLC7A11 expression and improving endothelial mitochondrial function.

While not yet a human treatment, this finding suggests that future therapies could target the specific signals fat cells send to blood vessels. For now, maintaining a healthy weight remains the most effective way to prevent these damaging signals from accumulating.

Sustained activation of pancreatic Y1 receptors improves beta-cell turnover, preserves beta-cell identity, and enhances insulin secretory responsiveness in rodent models of diabetes.

Sustained Y1 receptor activation improves beta-cell function in rodents, suggesting potential anti-diabetic benefits.

Acute exposure to high molecular weight advanced glycation end products (HMW-AGEs) impairs endothelium-dependent aortic relaxation.

Consuming foods high in advanced glycation end products (AGEs) can acutely harm blood vessel function. Avoiding highly processed, high-heat cooked foods may help maintain vascular health.

Intergenerational transmission of risk via microbiome, epigenetics, and noncoding RNAs (ncRNAs) contributes to the obesity epidemic by increasing susceptibility to weight gain in offspring of obese parents, independent of current energy intake.

If you have a family history of obesity, focus on a healthy diet and lifestyle for yourself and your children. This can help mitigate the biological risks transmitted through the microbiome and epigenetics.

Inadvertent exposure to GLP-1 receptor agonists during pregnancy does not appear to pose a significant teratogenic risk, with congenital abnormality rates in exposed pregnancies being lower than or comparable to placebo groups.

If you took a GLP-1 medication (like Ozempic or Wegovy) before knowing you were pregnant, current data from clinical trials does not show an increased risk of birth defects compared to women who did not take these medications. You should stop the medication as soon as you know you are pregnant and consult your doctor for standard prenatal care.